GU Cancers 2026 | Inclusion criteria of the EV-PRIME trial in muscle-invasive bladder cancer
Vadim Koshkin, MD, University of California, San Francisco, CA, comments on the endpoints and inclusion criteria of the EV-PRIME trial (NCT06470282) investigating the combination of enfortumab vedotin, pembrolizumab, and radiation in patients with muscle-invasive bladder cancer (MIBC), highlighting that the primary endpoint is clinical complete response at six months, with a focus on longer-term outcomes such as disease-free survival and overall survival. The trial aims to address both systemic and local control by combining systemic therapy with radiation, potentially improving outcomes and reducing local recurrences. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
